Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $49.4 million.

  • AtriCure's Accumulated Expenses rose 2348.67% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 2348.67%. This contributed to the annual value of $45.6 million for FY2024, which is 202.54% up from last year.
  • As of Q3 2025, AtriCure's Accumulated Expenses stood at $49.4 million, which was up 2348.67% from $40.3 million recorded in Q2 2025.
  • In the past 5 years, AtriCure's Accumulated Expenses ranged from a high of $49.4 million in Q3 2025 and a low of $25.3 million during Q1 2022
  • For the 5-year period, AtriCure's Accumulated Expenses averaged around $34.9 million, with its median value being $32.4 million (2021).
  • As far as peak fluctuations go, AtriCure's Accumulated Expenses surged by 8141.36% in 2021, and later crashed by 1473.26% in 2022.
  • Quarter analysis of 5 years shows AtriCure's Accumulated Expenses stood at $36.1 million in 2021, then decreased by 8.51% to $33.0 million in 2022, then soared by 35.31% to $44.7 million in 2023, then increased by 2.03% to $45.6 million in 2024, then grew by 8.3% to $49.4 million in 2025.
  • Its Accumulated Expenses was $49.4 million in Q3 2025, compared to $40.3 million in Q2 2025 and $33.2 million in Q1 2025.